LaFleur & Godfrey LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,801 shares of the medical equipment provider’s stock after purchasing an additional 6,280 shares during the period. Hologic accounts for about 2.0% of LaFleur & Godfrey LLC’s portfolio, making the stock its 17th largest position. LaFleur & Godfrey LLC owned about 0.08% of Hologic worth $7,734,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in HOLX. Capital World Investors acquired a new stake in Hologic in the 2nd quarter worth approximately $312,441,000. HealthCor Management L.P. acquired a new stake in Hologic in the 2nd quarter worth approximately $76,604,000. Columbus Circle Investors acquired a new stake in Hologic in the 2nd quarter worth approximately $54,511,000. Vanguard Group Inc. boosted its stake in Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after purchasing an additional 1,200,825 shares in the last quarter. Finally, Koch Industries Inc. boosted its stake in Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 1,142,138 shares in the last quarter. Institutional investors own 95.68% of the company’s stock.
HOLX has been the subject of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) cut shares of Hologic from a “conviction-buy” rating to a “buy” rating and lowered their target price for the stock from $48.00 to $47.00 in a research note on Thursday, August 3rd. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Bank of America Corporation reissued a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Hold” and an average price target of $47.77.
Shares of Hologic, Inc. (NASDAQ HOLX) traded down 0.91% during midday trading on Monday, reaching $36.90. 987,459 shares of the company traded hands. The stock’s 50-day moving average is $37.28 and its 200-day moving average is $41.49. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The stock has a market capitalization of $10.35 billion, a P/E ratio of 13.74 and a beta of 0.91.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.51 earnings per share. Equities analysts predict that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
In other Hologic news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total value of $276,908.24. Following the completion of the transaction, the director now owns 23,810 shares in the company, valued at $955,257.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders sold 30,775 shares of company stock valued at $1,175,662 in the last quarter. 0.79% of the stock is currently owned by company insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.